RECHERCHE :   Cancers hématologiques
Filtrage ? Le champ de filtrage permet de trier les études comportant le mot saisie. La recherche du mot se fait uniquement dans le contenu texte affiché à l'écran.
ETUDE PHASE SITE
CD45RA-DLI: A phase I clinical trial assessing prophylactic donor CD45RA-depleted lymphocyte infusions into patients transplanted with stem cell grafts from haploidentical donors after reduced intensity conditioning
Patients transplanted with stem cell grafts from haploidentical donors after reduced intensity conditioning
I
HUG
A phase 3 multicentre, randomized, prospective, open-label trial of Ibrutinib monotherapy vs fixed-duration Venetoclax plus Obinutuzumab vs fixed-duration Venetoclax plus Ibrutinib in patients with previously untreated chronic lymphocytic leukaemia (CLL17)
previously untreated chronic lymphocytic leukaemia
III
HUG
HOVON 150: A phase 3, multicenter, double-blind, randomized, placebo-controlled study of ivosidenib or enasidenib in combination with induction therapy and consolidation therapy followed by maintenance therapy in patients with newly diagnosed acute myeloid leukemia or myelodysplastic syndrome with excess blasts-2, with an IDH1 or IDH2 mutation, respectively, eligible for intensive chemotherapy.
Newly diagnosed acute myeloid leukemia or myelodysplastic syndrome with excess blasts-2, with an IDH1 or IDH2 mutation, respectively, eligible for intensive chemotherapy
III
HUG
HOVON 156: A Phase 3, Multicenter, Open-label, Randomized, Study of Gilteritinib Versus Midostaurin in Combination With Induction and Consolidation Therapy Followed by One-year Maintenance in Patients With Newly Diagnosed Acute Myeloid Leukemia (AML) or Myelodysplastic Syndromes With Excess Blasts-2 (MDS-EB2) With FLT3 Mutations Eligible for Intensive Chemotherapy
AML or MDS-EB2
III
HUG
SAKK 38/19 Assessing a ctDNA and PET-oriented therapy in patients with DLBCL A multicenter, open-label, phase II trial
Lymphome diffus à grandes cellules B
II
CHUV